A new independent 831 page research with title ‘Parkinson’s Disease – Pipeline Review, H2 2017’ guarantees you will remain better informed than your competition. The study covers geographic analysis and important players/vendors such as BBB Medicines BV, 4P Therapeutics LLC, AbbVie Inc, AC Immune SA With n-number of tables and figures examining the Parkinson’s disease the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2022
Parkinson’s disease is a neurodegenerative disorder characterized by movement dysfunctions. It causes involuntary shaking, stiffness and impaired locomotory functions. Age, genetic factors, head trauma, environmental factors, hormonal changes, etc are predisposing factors for Parkinson’s disease. Parkinson’s disease results in abnormal functioning or death of neurons. The neurons are responsible for the synthesis of neurotransmitter dopamine which is further responsible for the transmission of signals. The effect on the neurons blocks effective neurotransmission and may lead to eventual decline in movement and coordination.
Request a sample report @ https://www.htfmarketreport.com/sample-report/852550-parkinson-s-disease-pipeline-review-1
HTF Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Parkinson’s Disease – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Parkinson’s Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Parkinson’s Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson’s Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 8, 41, 42, 4, 190, 50 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 46 and 13 molecules, respectively.
Parkinson’s Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from HTF Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson’s Disease (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Parkinson’s Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Parkinson’s Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Parkinson’s Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson’s Disease (Central Nervous System)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Parkinson’s Disease (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Parkinson’s Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
2-BBB Medicines BV, 4P Therapeutics LLC, AbbVie Inc, AC Immune SA, Acorda Therapeutics Inc, Adamas Pharmaceuticals Inc, Addex Therapeutics Ltd, Aeolus Pharmaceuticals Inc, AFFiRiS AG, Amabiotics SAS, Amarantus Bioscience Holdings Inc, American Gene Technologies International Inc, Anavex Life Sciences Corp, Antoxis Ltd, Aoxing Pharmaceutical Company Inc, APeT Holding BV, ApoPharma Inc, Aposense Ltd, Araclon Biotech SL, ArmaGen Inc, Arrien Pharmaceuticals LLC, AstraZeneca Plc, Axovant Sciences Ltd, Berg LLC, Bial – Portela & Ca SA, Bio-Modeling Systems SAS, BioArctic AB, Bioasis Technologies Inc, BioElectron Technology Corp, Biogen Inc, BioHealthonomics Inc, Biopharm GmbH, BlueRock Therapeutics, BrainStorm Cell Therapeutics Inc, C4X Discovery Holdings PLC, Cantabio Pharmaceuticals Inc, Cardax Inc, Cell Cure Neurosciences Ltd, CHA Bio & Diostech Co Ltd, Chipscreen Biosciences Ltd, Clera Inc, Clevexel Pharma SAS, Corium International Inc, Crossject SA, Curemark LLC, Daewoong Pharmaceutical Co Ltd, Denali Therapeutics Inc, Diffusion Pharmaceuticals Inc, Easywell Biomedical Inc, Eli Lilly and Co, Energenesis Biomedical Co Ltd, Ensemble Therapeutics Corp, Evgen Pharma Plc, Evotec AG, Fabre-Kramer Pharmaceuticals Inc, Forma Therapeutics Inc, FPRT Bio Inc, Genecode AS, Generon (Shanghai) Corp Ltd, Genervon Biopharmaceuticals LLC, GenKyoTex SA, Genmab A/S, Genzyme Corp, H. Lundbeck AS, Hanmi Pharmaceuticals Co Ltd, Hemostemix Inc, Heptares Therapeutics Ltd, Herantis Pharma Plc, Hisamitsu Pharmaceutical Co Inc, HitGen LTD, ICB International Inc, Immungenetics AG, Impel NeuroPharma Inc, InnoMedica Holding AG, Intec Pharma Ltd, International Stem Cell Corp, Intra-Cellular Therapies Inc, Io Therapeutics Inc, Ionis Pharmaceuticals Inc, IRLAB Therapeutics AB, Jeil Pharmaceutical Co Ltd, Kainos Medicine Inc, Khondrion BV, KineMed Inc, Kissei Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, Lead Discovery Center GmbH, Living Cell Technologies Ltd, Longevity Biotech Inc, Luye Pharma Group Ltd, M et P Pharma AG, M’s Science Corp, M3 Biotechnology Inc, MedImmune LLC, Merck & Co Inc, Metabolic Solutions Development Company LLC, MimeTech Srl, Minerva Neurosciences Inc, Mission Therapeutics Ltd, Mitochon Pharmaceuticals Inc, Montisera Ltd, Motac Neuroscience Ltd, Neonc Technologies Inc, Netherlands Translational Research Center BV, Neuren Pharmaceuticals Ltd, NeuroDerm Ltd, NeuroGeneration Inc, NeuroNascent Inc, Neuronax SAS, NeurOp Inc, Neuropore Therapies Inc, New World Laboratories Inc, Newron Pharmaceuticals SpA, nLife Therapeutics SL, Novartis AG, Novo Nordisk AS, Omeros Corp, Oncodesign SA, OPKO Health Inc, Origenis GmbH, Orion Corporation, Oryzon Genomics SA, Oxford BioMedica Plc, ParkCell AB, Parkure Ltd, Peptron Inc, Pfizer Inc, Pharma Two B Ltd, Pharmaxis Ltd, Pharmicell Co Ltd, Pharnext SA, Phenomenome Discoveries Inc, Phoenix Biotechnology Inc, Plex Pharmaceuticals Inc, Prana Biotechnology Ltd, Prexton Therapeutics SA, Priavoid GmbH, Promius Pharma LLC, Prosetta Biosciences Inc, Proteostasis Therapeutics Inc, Prothena Corp Plc, QR Pharma Inc, reMYND NV, Rich Pharmaceuticals Inc, Sage Therapeutics Inc, SanBio Inc, Saniona AB, Serina Therapeutics Inc, Shire Plc, Sigma-Tau SpA, SignPath Pharma Inc, Signum Biosciences Inc, SK Biopharmaceuticals Co Ltd, STATegics Inc, Stealth BioTherapeutics Inc, Sumitomo Dainippon Pharma Co Ltd, Sun Pharma Advanced Research Company Ltd, Sunovion Pharmaceuticals Inc, Synthonics Inc, Takara Bio Inc, TauRx Therapeutics Ltd, TechnoPhage SA, Teikoku Pharma USA Inc, Teva Pharmaceutical Industries Ltd, Titan Pharmaceuticals Inc, Trevena Inc, UCB SA, UniQure NV, Varinel Inc, VistaGen Therapeutics Inc, Voyager Therapeutics Inc, vTv Therapeutics Inc, Wellstat Therapeutics Corp
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/852550-parkinson-s-disease-pipeline-review-1
Table of Contents
Parkinson’s Disease – Overview 9
Parkinson’s Disease – Product Development Milestones 783
Appendix 791List of Tables
Number of Products under Development for Parkinson’s Disease, H2 2017
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/852550-parkinson-s-disease-pipeline-review-1
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218